BROOKE GOLDEN: Open Payments
NPI 1457094161 · ALABASTER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$903 in 15 payments from 9 companies in 2025. Trend: 2023 $506 · 2024 $810 · 2025 $903
Food & beverage: $903
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $245 |
| Organon LLC | 2 | $184 |
| GENZYME CORPORATION | 1 | $149 |
| Lilly USA, LLC | 1 | $120 |
| Incyte Corporation | 1 | $108 |
| PFIZER INC. | 2 | $30 |
| Galderma Laboratories, L.P. | 1 | $25 |
| ABBVIE INC. | 1 | $21 |
| Kerecis Limited | 1 | $21 |
Products named: VTAMA, EBGLYSS, Opzelura, Rhapsido, CIBINQO, COSENTYX, SKYRIZI, Kerecis SurgiClose.
Industry payments across AL — which companies pay providers there.
